Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2091]

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC

Dr David Braun - Yale School of Medicine, New Haven, USA

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

Tumour microenvironment and circulating biomarkers predict response to...

Dr David Braun - Yale School of Medicine, New Haven, USA

Tumour microenvironment and circulating biomarkers predict response to immunotherapy in advanced RCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

ASCO 2025: Latest updates in mRCC

Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier...

ASCO 2025: Latest updates in mRCC ( Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier Puente )

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini

New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )

Social determinants and survival outcomes in early-onset colorectal cancer in...

Dr Jessica Paulus - Ontada, Boston, USA

Social determinants and survival outcomes in early-onset colorectal cancer in the US ( Dr Jessica Paulus - Ontada, Boston, USA )

Low frequency of dihydropyrimidine dehydrogenase variants in Mexican GI cancers...

Dr Enrique Soto Pérez de Celis - University of Colorado Cancer Center, Aurora...

Low frequency of dihydropyrimidine dehydrogenase variants in Mexican GI cancers should induce testing guideline reform ( Dr Enrique Soto Pérez de Celis - University of Colorado Cancer Center, Aurora, USA )

Molecular assay may help identify NSCLC patients who could benefit from...

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

ASCO 2025: Update on blood-based cancer assays

Dr Marie Wood - UCHealth University of Colorado Hospital, Aurora, USA

ASCO 2025: Update on blood-based cancer assays ( Dr Marie Wood - UCHealth University of Colorado Hospital, Aurora, USA )

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables...

Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing ( Dr Nadine M Tung - Beth Israel Deaconess Medical Center, Boston, USA )

ASCO 2025: Latest in EGFR positive NSCLC

Prof Pascale Tomasini, Prof Enriqueta Felip, Prof Nicolas Girard

ASCO 2025: Latest in EGFR positive NSCLC ( Prof Pascale Tomasini, Prof Enriqueta Felip, Prof Nicolas Girard )

Pro-inflammatory diets associated with worse outcomes for stage III colon cancer

Dr Sara K Char - Dana-Farber Cancer Institute, Boston, USA

Pro-inflammatory diets associated with worse outcomes for stage III colon cancer ( Dr Sara K Char - Dana-Farber Cancer Institute, Boston, USA )

Exercise programme may lower risk of recurrence and death for some colon cancer...

Dr Christopher Booth - Queen's University, Kingston, Canada

Exercise programme may lower risk of recurrence and death for some colon cancer survivors ( Dr Christopher Booth - Queen's University, Kingston, Canada )

More from ecancer